Introduction {#Sec1}
============

Animal welfare mandates adequate analgesia in sepsis models (Lilley E, Shock 2015; 43: 304). However, it is unclear which regimen is best to achieve this without interfering excessively with the scientific experiments. Nalbuphin, a non-controlled kappa opioid receptor agonist, has a short half live and a wide therapeutic range and might therefore be a useful analgesic for research animals.

Objectives {#Sec2}
==========

We test the efficacy and safety of intravenous nalbuphin in our rat model of fecal peritonitis. Here, we report its respiratory and hemodynamic effects in short-term experiments performed in non-septic rats during anaesthesia.

Methods {#Sec3}
=======

In this randomized, placebo-controlled, blinded study, spontaneously breathing male Wistar rats were anesthetized with isoflurane 3% (air flow 400 ml/min, FiO2 21%). Nalbuphin (or placebo) was injected subcutaneously at a dose of 1 mg/kg. After local anaesthesia with lidocaine, the left carotid artery and the right jugular vein were surgically cannulated. The isoflurane concentration was reduced to 2%. Intravenous nalbuphin (or placebo) was administered at two different doses (1 and 5 mg/kg/h). Nalbuphin concentration was measured in heparinised plasma by HPLC. Results are given as mean (standard error of the mean), p-values were calculated by a t-test.

Results {#Sec4}
=======

See table [1](#Tab1){ref-type="table"}.Table 1Results.Placebo (n=6)Nalbuphin 1 mg/kg/h (n=6)p-valuePlacebo (n=6)Nalbuphin 5 mg/kg iv (n=6)p-valueNalbuphin concentration \[mg/l\]22.9 (3.7)**Respiratory parameters**Respiration rate \[1/min\]55 (3)45 (2)0.0253 (4)41 (2)0.04pO2 \[kPa\]9.31 (0.41)7.86 (0.98)0.4110.1 (0.66)6.81 (0.36)0.02SaO2 \[%\]92.7 (1.2)83.9 (3.3)0.0993.6 (1.3)78 (2.7)0.02pCO2 \[kPa\]6.25 (0.31)7.72 (0.52)0.036.45 (0.53)8.49 (0.39)0.01**Hemodynamic parameters**Heart rate (1/min)409 (10)336 (12)0.00413 (14)332 (16)0.01Mean arterial pressure (mmHg)95 (6)78 (4)0.0492 (5)70 (3)0.01

Conclusions {#Sec5}
===========

Our results demonstrate that high-dose nalbuphin depresses respiratory rate, heart rate and mean arterial pressure in anesthetised rats. In order to investigate if the continuous intravenous infusion of nalbuphin influences our long-term sepsis model, further placebo-controlled studies in awake septic and non-septic rats are ongoing.
